Last reviewed · How we verify
Vincristin
At a glance
| Generic name | Vincristin |
|---|---|
| Also known as | Oncovin, VCR; Vincrystine |
| Sponsor | Arbeitsgemeinschaft medikamentoese Tumortherapie |
| Target | Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Acute lymphoid leukemia
- Burkitt's lymphoma
- Diffuse non-Hodgkin's lymphoma, large cell
- Follicular non-Hodgkin's lymphoma
- Hodgkin's disease
- Nephroblastoma
- Neuroblastoma
- Non-Hodgkin's lymphoma
- Rhabdomyosarcoma
Common side effects
- Hair loss
- Constipation
- Leukopenia
- Neuritic pain
- Paresthesia
- Sensory loss
- Nausea
- Vomiting
- Abdominal cramps
- Weight loss
- Anorexia
- Diarrhea
Serious adverse events
- Hepatic veno-occlusive disease
- Paralytic ileus
- Intestinal necrosis and/or perforation
- Bilateral vocal cord paralysis
- Anaphylaxis
- Myocardial infarction
- Coronary artery disease
- Urinary retention due to bladder atony
- Paralysis
- Foot drop
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vincristin CI brief — competitive landscape report
- Vincristin updates RSS · CI watch RSS
- Arbeitsgemeinschaft medikamentoese Tumortherapie portfolio CI